NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)
MMRF CoMMpass Study Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass) The primary...
Dec 9, 2011
NCT01402284: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
NCT01402284: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients KRd Carfilzomib is an experimental...
Dec 8, 2011
NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib
NCT01415882: Phase 2: Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib...
Dec 1, 2011
NCT01208662- Phase 3 - DETERMINATION Trial: Delayed vs Early Transplant with RVd & Revlimid Maint.
NDMM - DFCI 10-106 DETERMINATION Trial Delayed vs Early Transplant with Revlimid Maintenance and Anti-Myeloma Triple Therapy DFCI 10-106...
Dec 11, 2010
NCT01080391: Comparing Carfilzomib, Lenalidomide & Dex (CRd) vs Lenalidomide and Dex (Rd) - ASPIRE
THE ASPIRE TRIAL Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in...
Dec 10, 2010
NCT01169337: Phase 3 -Lenalidomide or Observation in Asymptomatic High-Risk Smoldering Myeloma E3A06
ECOG E3A06 ECOG-ACRIN Cancer Research Group ECOG E3A06 Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk...
Dec 10, 2010
NCT01029054: Phase 1/2: Carfilzomib and Lenalidomide With Dexamethasone Combination in NDMM
NCT01029054: Phase 1/2: Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple...
Dec 19, 2009
Phase 2: Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed MM
Leukemia; 2009 Jul Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in...
Dec 16, 2009
NCT00644228 : Phase 3 - Lenalidomide and Dexamethasone + / - Bortezomib in NDMM - SWOG S0777
Phase III trial SWOG S0777 SWOG0777 0777 Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously...
Dec 30, 2008
NCT00689936: Phase 3 - Lenalidomide+low dose dex vs Melphalan, Prednisone, Thalidomide in NDMM FIRST
FIRST study IFM 07-01 CC-5013-MM020 Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan,...
Dec 14, 2008
NCT00602641: Phase 3: Melphalan, Prednisone, and Thalidomide or Lenalidomide in NDMM Myeloma
ECOG-E1A06 ECOG-ACRIN Cancer Research Group NCT00602641: Phase 3: Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating...
Dec 6, 2008
NCT00507442: Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat NDMM EVOLUTION
EVOLUTION Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients (EVOLUTION)...
Dec 21, 2007
NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
RRMM Relapsed and Refractory Multiple Myeloma NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma...
Dec 14, 2007
Incorporating bortezomib into upfront treatment for multiple myeloma: early results total therapy 3
Br J Haematol 2007 Jul Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 Bart...
Dec 8, 2007
NCT00478218: Phase 2 : Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating New Myeloma
NCT00478218: Phase 2 : Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma...
Dec 7, 2007
NCT00378105: Phase 1/2: Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in NDMM
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma The purpose of this...
Dec 14, 2006
NCT00114101: Phase 3 - CALGB 100104 - Lenalidomide in Patients With MM Undergoing Auto Transplant
CALGB 100104 Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant NCT00114101: Phase 3 -...
Dec 29, 2005
NCT00111319: Phase 3 : VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in NDMM
Phase 3 VISTA Study phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and...
Dec 9, 2005
NCT00083551: UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma
This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after...
Dec 10, 2004